A Director at Stemline Therapeutics (NASDAQ: STML) is Buying Shares

By Carrie Williams

Yesterday, a Director at Stemline Therapeutics (STMLResearch Report), Alan S. Forman, bought shares of STML for $10.29K.

Following this transaction Alan S. Forman’s holding in the company was increased by 1.16% to a total of $847.7K.

See today’s analyst top recommended stocks >>

Based on Stemline Therapeutics’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $13.33 million and GAAP net loss of $14.89 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $21.04 million. The company has a one-year high of $18.22 and a one-year low of $7.82. Currently, Stemline Therapeutics has an average volume of 614.18K.

Starting in June 2019, STML received 20 Buy ratings in a row. Four different firms, including Cowen & Co. and Wedbush, currently also have a Buy rating on the stock.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701.